Credence Research Logo

Home » Healthcare » U.S. Platelet Rich Plasma (PRP) Market

U.S. Platelet Rich Plasma (PRP) Market By Type (Pure Platelet Rich Plasma (P-PRP), Leukocyte-Rich Platelet Rich Plasma (L-PRP), Leukocyte-Platelet-Rich Fibrin (L-PRF)); By Origin (Autologous, Homologous, Allogeneic); By Application (Orthopedic and Spinal Surgery, Cosmetic Surgery and Aesthetics, Neurosurgery, General Surgery, Others) – Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032

Report ID: 94405 | Report Format : Excel, PDF

REPORT ATTRIBUTE DETAILS
Historical Period 2020-2023
Base Year 2024
Forecast Period 2025-2032
U.S. Platelet Rich Plasma (PRP) MarketSize 2024  USD 254.08 million
U.S. Platelet Rich Plasma (PRP) Market, CAGR 12.81%
U.S. Platelet Rich Plasma (PRP) Market Size 2032 USD 666.40 million

Market Overview:

The U.S. Platelet Rich Plasma (PRP) Market is projected to grow from USD 254.08 million in 2024 to an estimated USD 666.40 million by 2032, with a compound annual growth rate (CAGR) of 12.81% from 2024 to 2032.

The U.S. Platelet-Rich Plasma (PRP) market is primarily driven by several key factors. One of the significant drivers is the rising incidence of musculoskeletal disorders, including osteoarthritis, tendonitis, and ligament injuries, particularly among the aging population and athletes. As these conditions increase, there is a growing demand for non-invasive treatment alternatives like PRP therapy. Additionally, advancements in regenerative medicine have enhanced the efficacy and appeal of PRP, establishing it as a promising solution for tissue repair and healing. The preference for minimally invasive procedures also contributes significantly to the market growth, as patients opt for treatments with shorter recovery times and fewer complications compared to traditional surgical interventions. Furthermore, increased healthcare expenditures in the U.S. are facilitating the adoption of innovative medical therapies, such as PRP, across various medical disciplines, including orthopedics, dermatology, and cosmetic surgery.

Regionally, the U.S. PRP market shows significant variation in adoption. The Western U.S. leads the market, driven by a high concentration of advanced medical facilities and an early embrace of regenerative therapies. Additionally, the region’s large sports and fitness community further drives the demand for PRP treatments. The Southern U.S. also contributes notably to the market, accounting for a significant percentage of PRP injections, as individuals seek alternative treatments for musculoskeletal injuries. Meanwhile, the Northeast and Midwest regions are seeing steady growth in PRP adoption, aided by expanding healthcare infrastructure, increasing awareness of regenerative medicine, and improving access to treatment options. Overall, the U.S. PRP market continues to expand, benefiting from technological advancements, favorable reimbursement policies, and growing patient preference for less invasive therapeutic options.

Access crucial information at unmatched prices!

Request your sample report today & start making informed decisions powered by Credence Research Inc.!

Download Sample

Market Insights:

  • The U.S. Platelet Rich Plasma (PRP) Market is projected to grow from USD 254.08 million in 2024 to USD 666.40 million by 2032, reflecting a compound annual growth rate (CAGR) of 12.81%.
  • The global Platelet Rich Plasma (PRP) market is projected to grow from USD 729.75 million in 2024 to USD 1,895.64 million by 2032, at a CAGR of 12.67% during the forecast period.
  • The rising prevalence of musculoskeletal disorders, such as osteoarthritis and tendonitis, is a significant driver of market growth, particularly among the aging population and athletes who require non-invasive treatment options like PRP.
  • Patient preference for minimally invasive therapies is accelerating the adoption of PRP, as it offers reduced recovery times and fewer complications compared to traditional surgery, making it an appealing alternative for various conditions.
  • Technological advancements in regenerative medicine have enhanced PRP’s efficacy, expanding its applications in orthopedics, sports medicine, and cosmetic dermatology, where it is used for tissue regeneration and hair restoration.
  • Increasing healthcare expenditures in the U.S. and improvements in insurance coverage for regenerative therapies are making PRP treatments more accessible to a wider range of patients, further boosting its market growth.
  • High treatment costs remain a significant challenge, with many patients finding PRP therapy unaffordable due to the need for specialized equipment and expertise, and limited insurance coverage for cosmetic procedures.
  • The lack of standardized procedures for PRP preparation and administration is contributing to inconsistent results, highlighting the need for uniform protocols to ensure the effectiveness and safety of the therapy.

Report scoope

This report segments the U.S. Platelet Rich Plasma (PRP) Market as follow

U.S. Platelet Rich Plasma (PRP) Market

Market Drivers:

Increasing Prevalence of Musculoskeletal Disorders

The rising prevalence of musculoskeletal disorders, such as osteoarthritis, tendonitis, and ligament injuries, is a primary driver of growth in the U.S. Platelet-Rich Plasma (PRP) Market. These conditions are becoming more common, particularly among the aging population and athletes who experience higher rates of joint and tendon injuries. As patients seek effective, non-invasive treatment alternatives, PRP therapy is gaining traction due to its ability to promote healing and tissue regeneration. With the increasing incidence of such disorders, the demand for treatments like PRP continues to grow, making it a key driver of the market.

  • For example, a study cited in the National Institutes of Health database found that athletes treated with PRP returned to play in an average of 21.1 days, compared to 25 days for those receiving standard conservative therapy, demonstrating a statistically significant improvement in recovery speed.

Preference for Minimally Invasive Therapies

There is a significant shift in patient preferences towards minimally invasive therapies, which has contributed to the growth of the U.S. Platelet-Rich Plasma (PRP) Market. PRP injections are an appealing alternative to traditional surgery, offering patients reduced recovery times and fewer complications. As healthcare providers seek to meet this demand, PRP has become an attractive option for treating various conditions, including musculoskeletal injuries, arthritis, and even aesthetic procedures. The growing trend of opting for less invasive procedures has accelerated the adoption of PRP therapy across multiple medical fields.

  • For example, RealSelf, a leading online platform for cosmetic treatment reviews, reported that 84% of users who underwent PRP-based facial rejuvenation procedures rated the treatment as “worth it” in 2023.

Advancements in Regenerative Medicine

Technological advancements in regenerative medicine are another major factor propelling the U.S. Platelet-Rich Plasma (PRP) Market. Ongoing research and clinical studies have demonstrated the effectiveness of PRP in tissue regeneration and wound healing, particularly in orthopedics and sports medicine. The increasing understanding of PRP’s potential has expanded its applications, leading to its use in cosmetic dermatology and hair restoration. These advancements are fostering greater acceptance of PRP therapies, as both healthcare professionals and patients recognize their benefits in promoting long-term healing and recovery.

Growing Healthcare Expenditures and Insurance Coverage

The rising healthcare expenditures in the U.S. are facilitating the widespread adoption of innovative therapies like PRP. With higher spending, healthcare systems are increasingly able to incorporate advanced treatments into their offerings. Furthermore, improvements in insurance coverage for regenerative therapies have helped make PRP treatments more accessible to a broader range of patients. As more insurance providers cover PRP injections, the treatment becomes a viable option for individuals seeking non-surgical solutions, thus contributing to the market’s growth. This financial accessibility is driving the increased adoption of PRP therapy across various healthcare sectors.

Market Trends:

Increasing Adoption of PRP in Aesthetic Medicine

The U.S. Platelet Rich Plasma (PRP) Market is witnessing a significant trend towards the adoption of PRP therapies in aesthetic medicine. Over the years, PRP has gained popularity for non-invasive cosmetic treatments, particularly for facial rejuvenation and hair restoration. It is increasingly used in dermatology for treatments aimed at reducing wrinkles, improving skin texture, and promoting hair regrowth, especially in individuals with androgenic alopecia. This growing trend reflects a shift in consumer preference for natural, less invasive procedures that offer minimal downtime compared to traditional surgical options, further driving the expansion of PRP in the aesthetic space.

  • For example, MetropolitanMD in Chicago offers PRP treatments for facial rejuvenation and hair loss, highlighting that PRP can stimulate collagen production, improve skin elasticity, and activate dormant hair follicles, leading to enhanced skin texture and hair growth for both men and women.

Expansion of PRP Applications in Orthopedic and Sports Medicine

Another key trend in the U.S. Platelet Rich Plasma (PRP) Market is the expansion of its applications in orthopedic and sports medicine. PRP therapy has proven to be effective in treating a variety of musculoskeletal injuries, including tendonitis, ligament sprains, and osteoarthritis. Athletes and active individuals increasingly turn to PRP as an alternative to traditional surgeries due to its potential to accelerate healing and reduce recovery time. The growing acceptance of PRP in treating chronic injuries and its ability to enhance tissue repair are significant factors contributing to its rising usage in these medical fields.

Rising Focus on Personalized and Regenerative Medicine

Personalized and regenerative medicine is becoming a prominent trend in the U.S. Platelet Rich Plasma (PRP) Market. PRP therapy is increasingly recognized for its ability to harness the body’s natural healing mechanisms by using a patient’s own blood to promote tissue repair. This aligns with the broader trend in healthcare towards more individualized treatments tailored to each patient’s needs. As personalized medicine continues to evolve, the role of PRP in regenerative therapies expands, making it a valuable option for treating a range of conditions, from musculoskeletal injuries to skin regeneration.

Advancements in PRP Processing Technologies

Advancements in PRP processing technologies are also driving trends in the U.S. Platelet Rich Plasma (PRP) Market. New and improved devices are being developed to optimize the preparation and concentration of platelets, resulting in more efficient and effective treatments. These innovations enhance the overall quality of PRP injections, making them more accessible and reliable for both healthcare providers and patients. The continuous improvements in PRP processing techniques contribute to the growing adoption of PRP in a variety of medical fields, from orthopedics to aesthetic medicine, thus supporting the market’s expansion.

  • For example, Arthrex’s Angel System allows clinicians to customize platelet and plasma concentrations, resulting in tailored treatments for specific patient needs.

Market Challenges Analysis:

High Cost of PRP Treatment

One of the major challenges facing the U.S. Platelet Rich Plasma (PRP) Market is the high cost of treatment. While PRP therapy is considered an effective, non-surgical alternative for various medical and cosmetic conditions, its affordability remains a significant barrier for many patients. The costs associated with the preparation of PRP, the need for specialized equipment, and the expertise required for administration contribute to its high price. Many insurance providers do not cover PRP treatments, especially for cosmetic applications, which limits its accessibility to a broader population. The high upfront costs of treatment may prevent some individuals from opting for PRP, particularly in an environment where other treatments are available at lower prices.

Regulatory and Standardization Challenges

One of the key challenges in the North America Platelet Rich Plasma (PRP) Market is the lack of standardized protocols and inconsistent regulations. While PRP therapy is widely used across various medical and aesthetic fields, there is no uniform standard for its preparation and application. Different clinics and practitioners may use varying methods for centrifugation and platelet concentration, leading to discrepancies in treatment outcomes. The absence of standardized guidelines from regulatory bodies can create confusion for patients and healthcare providers, potentially affecting patient safety and treatment efficacy. Regulatory agencies, such as the FDA, have not fully classified PRP as a medical product, which leads to a lack of clarity on its approval process. This regulatory ambiguity hampers market growth by limiting wider adoption and creating inconsistencies in quality control.

  • For instance, PRP preparation systems are brought to market in the United States through the FDA’s 510(k) pathway, which only requires that new devices are “substantially equivalent” to an already cleared predicate device-typically for mixing with bone graft materials in orthopedics.

Market Opportunities:

The growing demand for non-invasive cosmetic treatments presents a significant opportunity for the U.S. Platelet Rich Plasma (PRP) Market. PRP is increasingly being used for facial rejuvenation, hair restoration, and skin regeneration, particularly among individuals seeking natural and less invasive alternatives to surgery. As consumer awareness of PRP’s benefits in aesthetics continues to rise, more patients are opting for these treatments, creating a larger market base. The increasing popularity of PRP in dermatology and cosmetic surgery offers a promising growth opportunity, especially as innovations in treatment techniques continue to improve results and patient satisfaction.

The U.S. Platelet Rich Plasma (PRP) Market has substantial growth potential through its integration with broader regenerative medicine trends. PRP’s ability to promote tissue healing and regeneration aligns with the growing emphasis on personalized and regenerative therapies. Expanding PRP applications in orthopedics, sports medicine, and chronic pain management could significantly boost its market share. With advancements in processing technologies and growing recognition of its therapeutic benefits, PRP can play an integral role in the development of personalized treatment plans, further strengthening its position within the regenerative medicine field.

Market Segmentation Analysis:

The U.S. Platelet Rich Plasma (PRP) Market is segmented based on type, origin, and application, each contributing to its growth across various medical fields.

By Type, the market includes Pure Platelet Rich Plasma (P-PRP), Leukocyte-Rich Platelet Rich Plasma (L-PRP), and Leukocyte-Platelet-Rich Fibrin (L-PRF). P-PRP, which is primarily used for tissue regeneration, is gaining popularity due to its ability to concentrate platelets, making it suitable for a wide range of therapeutic applications. L-PRP and L-PRF, which contain a higher concentration of white blood cells, are typically used in treating conditions where inflammation control is essential, such as in orthopedic and aesthetic procedures.

By Origin, the market is divided into Autologous, Homologous, and Allogeneic PRP. Autologous PRP, derived from the patient’s own blood, dominates the market due to its safety and reduced risk of immune response. Homologous and Allogeneic PRP are gaining traction in cases where patients have difficulty producing sufficient platelet concentrations, though their use remains more limited.

By Application, the market spans Orthopedic and Spinal Surgery, Cosmetic Surgery and Aesthetics, Neurosurgery, General Surgery, and other specialized fields. Orthopedic applications lead the market, driven by PRP’s ability to treat musculoskeletal injuries and joint disorders. The growing use of PRP in cosmetic surgery and aesthetics further boosts its market share, with a notable rise in treatments for skin rejuvenation and hair restoration.

Segmentation:

By Type:

  • Pure Platelet Rich Plasma (P-PRP)
  • Leukocyte-Rich Platelet Rich Plasma (L-PRP)
  • Leukocyte-Platelet-Rich Fibrin (L-PRF)

By Origin:

  • Autologous
  • Homologous
  • Allogeneic

By Application:

  • Orthopedic and Spinal Surgery
  • Cosmetic Surgery and Aesthetics
  • Neurosurgery
  • General Surgery
  • Others

Regional Analysis:

Western U.S. Market

The Western U.S. holds the largest share of the U.S. Platelet Rich Plasma (PRP) Market, accounting for approximately 40% of the total market. This region is a hub for advanced healthcare facilities and cutting-edge medical technologies, which contribute significantly to the adoption of PRP treatments. The high concentration of sports professionals and active individuals seeking non-surgical treatments for musculoskeletal injuries further drives market growth. California, in particular, is a key market due to its strong presence in both the healthcare and wellness industries. The growing demand for PRP in aesthetic procedures, such as facial rejuvenation and hair restoration, is also significant in this region, adding to its dominant market share.

Southern U.S. Market

The Southern U.S. is another critical region for the U.S. Platelet Rich Plasma (PRP) Market, contributing roughly 30% of the market share. This region has witnessed a rapid increase in the adoption of PRP therapy, especially in orthopedic and sports medicine applications. The South’s focus on healthcare access and patient-centered care has led to greater PRP therapy availability, with numerous clinics and medical centers offering these treatments. States like Texas and Florida have seen an upsurge in the demand for PRP, driven by an aging population and active lifestyles that necessitate regenerative therapies. The expansion of cosmetic PRP treatments, particularly in dermatology, further supports the market’s growth in this region.

Northeastern and Midwestern U.S. Markets

The Northeastern and Midwestern U.S. markets collectively account for approximately 30% of the U.S. Platelet Rich Plasma (PRP) Market. These regions are experiencing steady growth in PRP adoption, driven by improving healthcare infrastructure and increasing patient awareness. The Northeastern states, particularly New York and Pennsylvania, have established a strong presence of medical institutions specializing in PRP for both orthopedic and cosmetic procedures. In the Midwest, cities like Chicago are seeing growing interest in PRP as an effective treatment for musculoskeletal injuries, joint disorders, and aesthetic concerns. These regions benefit from a combination of advanced healthcare systems, research institutions, and increasing demand for non-invasive, regenerative therapies.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Customize Now

Key Player Analysis:

  • EmCyte Corporation
  • RegenLab
  • Arthrex Inc.
  • Harvest Technologies
  • Cellmedix

Competitive Analysis:

The U.S. Platelet Rich Plasma (PRP) Market is highly competitive, with numerous key players striving to expand their market share through innovation and strategic partnerships. Leading companies such as Arthrex, Inc., EmCyte Corporation, and RegenLab USA dominate the market by offering advanced PRP systems and technologies. These companies focus on enhancing the efficiency and effectiveness of PRP treatments, ensuring higher quality products and better clinical outcomes. Smaller companies also contribute to market growth by introducing more affordable, user-friendly PRP kits tailored for smaller practices and clinics. Intense competition is driven by the increasing demand for non-invasive, regenerative treatments in orthopedics, dermatology, and aesthetics. Companies are investing heavily in research and development to improve PRP processing technology and expand its applications across various medical specialties. The market remains dynamic, with established players and new entrants competing for a share in the growing regenerative medicine sector.

Recent Developments:

  • In April 2025, Arthrex, Inc. launched the ACP Max™ Platelet-Rich Plasma System, which builds on previous PRP devices by enabling a larger blood draw and higher platelet concentration through its unique double-syringe, double-spin design. This system is designed to efficiently concentrate platelets and growth factors for point-of-care use, marking a significant advancement in Arthrex’s PRP product offerings.
  • In January 2024, Arthrex showcased the use of its ACP Max system, which is designed for creating highly concentrated platelet-rich plasma (PRP) with low neutrophil content. This demonstration highlighted Arthrex’s commitment to advancing PRP technology for improved patient outcomes in regenerative medicine and orthopedic applications
  • In October 2024, Terumo Blood and Cell Technologies (Terumo BCT) entered a 10-year partnership with the Sanquin Blood Supply Foundation in the Netherlands to automate the country’s blood processing facilities using the Reveos™ Automated Blood Processing System. This agreement aims to enhance efficiency and increase the production of essential blood products, including platelets and plasma, by reducing manual steps and streamlining operations.

Market Concentration & Characteristics:

The U.S. Platelet Rich Plasma (PRP) Market is moderately concentrated, with a few key players dominating the landscape. Major companies, such as Arthrex, Inc., EmCyte Corporation, and RegenLab USA, hold significant market shares due to their established product lines and strong brand presence. These companies are known for offering advanced PRP systems and technologies that cater to a wide range of medical applications, from orthopedics to aesthetics. Smaller players in the market often focus on niche segments, providing cost-effective solutions and targeting smaller healthcare providers. The market is characterized by continuous innovation, with companies investing in research and development to improve PRP processing and expand its clinical applications. This dynamic competitive environment drives market growth, as companies seek to capture opportunities in both established and emerging sectors of regenerative medicine.

Report Coverage:

The research report offers an in-depth analysis based on type, origin, and application. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.

Future Outlook:

  • The U.S. Platelet Rich Plasma (PRP) Market is expected to experience consistent growth, driven by increasing demand for non-invasive therapies.
  • Advancements in PRP processing technologies will improve the efficiency and effectiveness of treatments, attracting more healthcare providers.
  • The growing popularity of PRP in cosmetic treatments, such as facial rejuvenation and hair restoration, will expand its market share.
  • Increased awareness of PRP’s benefits in orthopedic and sports medicine will further boost its adoption in musculoskeletal treatments.
  • Aging populations seeking alternatives to traditional surgeries will continue to drive PRP usage in various therapeutic applications.
  • The expansion of insurance coverage for regenerative therapies will make PRP treatments more accessible to a broader demographic.
  • Emerging clinical applications, including neurosurgery and general surgery, will create new growth opportunities for PRP.
  • Regulatory approvals and standardization in PRP procedures will enhance treatment consistency and safety.
  • The rise in medical tourism, particularly for aesthetic PRP treatments, will contribute to market expansion.
  • Ongoing research into the efficacy of PRP for chronic pain management and tissue regeneration will open new avenues for growth.

CHAPTER NO. 1 : INTRODUCTION 17

1.1.1. Report Description 17

Purpose of the Report 17

USP & Key Types 17

1.1.2. Key Benefits for Stakeholders 17

1.1.3. Target Audience 18

1.1.4. Report Scope 18

CHAPTER NO. 2 : EXECUTIVE SUMMARY 19

2.1. U.S. Platelet Rich Plasma (PRP) Market Snapshot 19

2.1.1. U.S. Platelet Rich Plasma (PRP) Market, 2018 – 2032 (USD Million) 20

CHAPTER NO. 3 : U.S. PLATELET RICH PLASMA (PRP) MARKET – INDUSTRY ANALYSIS 21

3.1. Introduction 21

3.2. Market Drivers 22

3.2.1. Enhanced Patient Outcomes Leading to Positive Word-of-Mouth 22

3.2.2. Development of Home-Based PRP Systems 23

3.3. Market Restraints 24

3.3.1. Perceived Lack of Immediate Results Compared to Alternatives 24

3.4. Market Opportunities 25

3.4.1. Market Opportunity Analysis 25

3.5. Porter’s Five Forces Analysis 26

CHAPTER NO. 4 : ANALYSIS COMPETITIVE LANDSCAPE 27

4.1. Company Market Share Analysis – 2023 27

4.1.1. U.S. Platelet Rich Plasma (PRP) Market: Company Market Share, by Revenue, 2024 27

4.1.2. U.S. Platelet Rich Plasma (PRP) Market: Top 6 Company Market Share, by Revenue, 2024 27

4.1.3. U.S. Platelet Rich Plasma (PRP) Market: Top 3 Company Market Share, by Revenue, 2024 28

4.2. U.S. Platelet Rich Plasma (PRP) Market Company Revenue Market Share, 2024 29

4.3. Company Assessment Metrics, 2024 30

4.3.1. Stars 30

4.3.2. Emerging Leaders 30

4.3.3. Pervasive Players 30

4.3.4. Participants 30

4.4. Start-ups /SMEs Assessment Metrics, 2024 30

4.4.1. Progressive Companies 30

4.4.2. Responsive Companies 30

4.4.3. Dynamic Companies 30

4.4.4. Starting Blocks 30

4.5. Strategic Developments 31

4.5.1. Acquisitions & Mergers 31

New Product Launch 31

U.S. Expansion 31

4.6. Key Players Product Matrix 32

CHAPTER NO. 5 : PESTEL & ADJACENT MARKET ANALYSIS 33

5.1. PESTEL 33

5.1.1. Political Factors 33

5.1.2. Economic Factors 33

5.1.3. Social Factors 33

5.1.4. Technological Factors 33

5.1.5. Environmental Factors 33

5.1.6. Legal Factors 33

5.2. Adjacent Market Analysis 33

CHAPTER NO. 6 : U.S. PLATELET RICH PLASMA (PRP) MARKET – BY TYPE SEGMENT ANALYSIS 34

6.1. U.S. Platelet Rich Plasma (PRP) Market Overview, by Type Segment 34

6.1.1. U.S. Platelet Rich Plasma (PRP) Market Revenue Share, By Type, 2023 & 2032 35

6.1.2. U.S. Platelet Rich Plasma (PRP) Market Attractiveness Analysis, By Type 36

6.1.3. Incremental Revenue Growth Opportunity, by Type, 2024 – 2032 36

6.1.4. U.S. Platelet Rich Plasma (PRP) Market Revenue, By Type, 2018, 2023, 2027 & 2032 37

6.2. Pure Platelet Rich Plasma (P-PRP) 38

6.3. Leukocyte-Rich Platelet Rich Plasma (L-PRP) 39

6.4. Leukocyte-Platelet-Rich Fibrin (L-PRF) 40

CHAPTER NO. 7 : U.S. PLATELET RICH PLASMA (PRP) MARKET – BY ORIGIN SEGMENT ANALYSIS 41

7.1. U.S. Platelet Rich Plasma (PRP) Market Overview, by Origin Segment 41

7.1.1. U.S. Platelet Rich Plasma (PRP) Market Revenue Share, By Origin, 2023 & 2032 42

7.1.2. U.S. Platelet Rich Plasma (PRP) Market Attractiveness Analysis, By Origin 43

7.1.3. Incremental Revenue Growth Opportunity, by Origin, 2024 – 2032 43

7.1.4. U.S. Platelet Rich Plasma (PRP) Market Revenue, By Origin, 2018, 2023, 2027 & 2032 44

7.2. Autologous 45

7.3. Homologous 46

7.4. Allogeneic 47

CHAPTER NO. 8 : U.S. PLATELET RICH PLASMA (PRP) MARKET – BY APPLICATION SEGMENT ANALYSIS 48

8.1. U.S. Platelet Rich Plasma (PRP) Market Overview, by Application Segment 48

8.1.1. U.S. Platelet Rich Plasma (PRP) Market Revenue Share, By Application, 2023 & 2032 49

8.1.2. U.S. Platelet Rich Plasma (PRP) Market Attractiveness Analysis, By Application 50

8.1.3. Incremental Revenue Growth Opportunity, by Application, 2024 – 2032 50

8.1.4. U.S. Platelet Rich Plasma (PRP) Market Revenue, By Application, 2018, 2023, 2027 & 2032 51

8.2. Orthopedic and Spinal Surgery 52

8.3. Cosmetic Surgery and Aesthetics 53

8.4. Neurosurgery 54

8.5. General Surgery 55

8.6. Others 56

CHAPTER NO. 9 : U.S. PLATELET RICH PLASMA (PRP) MARKET – ANALYSIS 57

9.1. Type 57

9.1.1. U.S. Platelet Rich Plasma (PRP) Market Revenue, By Type, 2018 – 2023 (USD Million) 57

9.1.2. U.S. Platelet Rich Plasma (PRP) Market Revenue, By Type, 2024 – 2032 (USD Million) 57

9.2. Origin 58

9.2.1. U.S. Platelet Rich Plasma (PRP) Market Revenue, By Origin, 2018 – 2023 (USD Million) 58

9.2.2. U.S. Platelet Rich Plasma (PRP) Market Revenue, By Origin, 2024 – 2032 (USD Million) 58

9.3. Application 59

9.3.1. U.S. Platelet Rich Plasma (PRP) Market Revenue, By Application, 2018 – 2023 (USD Million) 59

9.3.2. U.S. Platelet Rich Plasma (PRP) Market Revenue, By Application, 2024 – 2032 (USD Million) 59

CHAPTER NO. 10 : COMPANY PROFILES 60

10.1. EmCyte Corporation 60

10.1.1. Company Overview 60

10.1.2. Product Portfolio 60

10.1.3. Swot Analysis 60

10.1.4. Business Strategy 61

10.1.5. Financial Overview 61

10.2. RegenLab 62

10.3. Arthrex Inc. 62

10.4. Harvest Technologies 62

10.5. Cellmedix 62

10.6. Company 6 62

10.7. Company 7 62

10.8. Company 8 62

10.9. Company 9 62

10.10. Company 10 62

 

List of Figures

FIG NO. 1. U.S. Platelet Rich Plasma (PRP) Market Revenue, 2018 – 2032 (USD Million) 20

FIG NO. 2. Porter’s Five Forces Analysis for U.S. Platelet Rich Plasma (PRP) Market 26

FIG NO. 3. Company Share Analysis, 2024 27

FIG NO. 4. Company Share Analysis, 2024 27

FIG NO. 5. Company Share Analysis, 2024 28

FIG NO. 6. U.S. Platelet Rich Plasma (PRP) Market – Company Revenue Market Share, 2024 29

FIG NO. 7. U.S. Platelet Rich Plasma (PRP) Market Revenue Share, By Type, 2023 & 2032 35

FIG NO. 8. Market Attractiveness Analysis, By Type 36

FIG NO. 9. Incremental Revenue Growth Opportunity by Type, 2024 – 2032 36

FIG NO. 10. U.S. Platelet Rich Plasma (PRP) Market Revenue, By Type, 2018, 2023, 2027 & 2032 37

FIG NO. 11. U.S. Platelet Rich Plasma (PRP) Market for Pure Platelet Rich Plasma (P-PRP), Revenue (USD Million) 2018 – 2032 38

FIG NO. 12. U.S. Platelet Rich Plasma (PRP) Market for Leukocyte-Rich Platelet Rich Plasma (L-PRP), Revenue (USD Million) 2018 – 2032 39

FIG NO. 13. U.S. Platelet Rich Plasma (PRP) Market for Leukocyte-Platelet-Rich Fibrin (L-PRF), Revenue (USD Million) 2018 – 2032 40

FIG NO. 14. U.S. Platelet Rich Plasma (PRP) Market Revenue Share, By Origin, 2023 & 2032 42

FIG NO. 15. Market Attractiveness Analysis, By Origin 43

FIG NO. 16. Incremental Revenue Growth Opportunity by Origin, 2024 – 2032 43

FIG NO. 17. U.S. Platelet Rich Plasma (PRP) Market Revenue, By Origin, 2018, 2023, 2027 & 2032 44

FIG NO. 18. U.S. Platelet Rich Plasma (PRP) Market for Autologous, Revenue (USD Million) 2018 – 2032 45

FIG NO. 19. U.S. Platelet Rich Plasma (PRP) Market for Homologous, Revenue (USD Million) 2018 – 2032 46

FIG NO. 20. U.S. Platelet Rich Plasma (PRP) Market for Allogeneic, Revenue (USD Million) 2018 – 2032 47

FIG NO. 21. U.S. Platelet Rich Plasma (PRP) Market Revenue Share, By Application, 2023 & 2032 49

FIG NO. 22. Market Attractiveness Analysis, By Application 50

FIG NO. 23. Incremental Revenue Growth Opportunity by Application, 2024 – 2032 50

FIG NO. 24. U.S. Platelet Rich Plasma (PRP) Market Revenue, By Application, 2018, 2023, 2027 & 2032 51

FIG NO. 25. U.S. Platelet Rich Plasma (PRP) Market for Orthopedic and Spinal Surgery, Revenue (USD Million) 2018 – 2032 52

FIG NO. 26. U.S. Platelet Rich Plasma (PRP) Market for Cosmetic Surgery and Aesthetics, Revenue (USD Million) 2018 – 2032 53

FIG NO. 27. U.S. Platelet Rich Plasma (PRP) Market for Neurosurgery, Revenue (USD Million) 2018 – 2032 54

FIG NO. 28. U.S. Platelet Rich Plasma (PRP) Market for General Surgery, Revenue (USD Million) 2018 – 2032 55

FIG NO. 29. U.S. Platelet Rich Plasma (PRP) Market for Others, Revenue (USD Million) 2018 – 2032 56

 

List of Tables

TABLE NO. 1. : U.S. Platelet Rich Plasma (PRP) Market: Snapshot 19

TABLE NO. 2. : Drivers for the U.S. Platelet Rich Plasma (PRP) Market: Impact Analysis 22

TABLE NO. 3. : Restraints for the U.S. Platelet Rich Plasma (PRP) Market: Impact Analysis 24

TABLE NO. 4. : U.S. Platelet Rich Plasma (PRP) Market Revenue, By Type, 2018 – 2023 (USD Million) 57

TABLE NO. 5. : U.S. Platelet Rich Plasma (PRP) Market Revenue, By Type, 2024 – 2032 (USD Million) 57

TABLE NO. 6. : U.S. Platelet Rich Plasma (PRP) Market Revenue, By Origin, 2018 – 2023 (USD Million) 58

TABLE NO. 7. : U.S. Platelet Rich Plasma (PRP) Market Revenue, By Origin, 2024 – 2032 (USD Million) 58

TABLE NO. 8. : U.S. Platelet Rich Plasma (PRP) Market Revenue, By Application, 2018 – 2023 (USD Million) 59

TABLE NO. 9. : U.S. Platelet Rich Plasma (PRP) Market Revenue, By Application, 2024 – 2032 (USD Million) 59

 

Request Sample

Request Free Sample

We prioritize the confidentiality and security of your data. Our promise: your information remains private.

Ready to Transform Data into Decisions?

Request Your Sample Report and Start Your Journey of Informed Choices

Providing the strategic compass for industry titans.

cr-clients-logos

Frequently Asked Questions

What is the current size of the U.S. Platelet Rich Plasma (PRP) Market?

The U.S. Platelet Rich Plasma (PRP) Market is projected to grow from USD 254.08 million in 2024 to USD 666.40 million by 2032, with a CAGR of 12.81%.

What factors are driving the growth of the U.S. Platelet Rich Plasma (PRP) Market?

The market growth is driven by the increasing prevalence of musculoskeletal disorders, advancements in regenerative medicine, a preference for minimally invasive procedures, and rising healthcare expenditures.

What are some challenges faced by the U.S. Platelet Rich Plasma (PRP) Market?

The market faces challenges including high treatment costs, lack of standardization in PRP procedures, and limited insurance coverage for treatments, especially for cosmetic applications.

Who are the major players in the U.S. Platelet Rich Plasma (PRP) Market?

Major players include Arthrex, Inc., EmCyte Corporation, RegenLab USA, and other key companies providing PRP systems and kits.

About Author

Shweta Bisht

Shweta Bisht

Healthcare & Biotech Analyst

Shweta is a healthcare and biotech researcher with strong analytical skills in chemical and agri domains.

View Profile

Related Reports By Keyword

U.S. Plus Size Women’s Clothing Market

U.S. Plus Size Women’s Clothing Market size was valued at USD 58871.49 million in 2023 and is anticipated to reach USD 101938.14 million by 2032, at a CAGR of 6.29% during the forecast period.

U.S. Effects Pedal Power Supplies Market

The U.S. Effects Pedal Power Supplies Market size was valued at USD 80.3 million in 2018 to USD 89.8 million in 2024 and is anticipated to reach USD 122.1 million by 2032, at a CAGR of 3.92% during the forecast period.

U.S. Instrument (Audio) Cables Market

The U.S. Instrument (Audio) Cables Market size was valued at USD 54.6 million in 2018 to USD 64.5 million in 2024 and is anticipated to reach USD 94.8 million by 2032, at a CAGR of 4.93% during the forecast period.

U.S. Fretted Instrument String Market

The U.S. Fretted Instrument String Market size was valued at USD 98.6 million in 2018 to USD 122.5 million in 2024 and is anticipated to reach USD 198.1 million by 2032, at a CAGR of 6.19% during the forecast period.

U.S. Dairy Market

The U.S. Dairy Market size was valued at USD 62.84 billion in 2018 to USD 87.61 billion in 2024 and is anticipated to reach USD 136.45 billion by 2032, at a CAGR of 5.69% during the forecast period.

U.S. Golf Cart Market

U.S. Golf Cart Market size was valued at USD 262.42 million in 2018 to USD 316.38 million in 2024 and is anticipated to reach USD 448.72 million by 2032, at a CAGR of 3.93% during the forecast period.

U.S. Golf Club Market

The U.S. Golf Club Market size was valued at USD 715.47 million in 2018 to USD 831.13 million in 2024 and is anticipated to reach USD 1,047.48 million by 2032, at a CAGR of 2.93% during the forecast period.

U.S. Golf Training Aids Market

The U.S. Golf Training Aids Market size was valued at USD 112.89 million in 2018 to USD 162.62 million in 2024 and is anticipated to reach USD 228.92 million by 2032, at a CAGR of 4.44% during the forecast period.

U.S. Golf Apparel Market

The U.S. Golf Apparel Market size was valued at USD 607.09 million in 2018 to USD 739.56 million in 2024 and is anticipated to reach USD 1,025.69 million by 2032, at a CAGR of 4.16% during the forecast period.

Purchase Options

The report comes as a view-only PDF document, optimized for individual clients. This version is recommended for personal digital use and does not allow printing. Use restricted to one purchaser only.
$2999

To meet the needs of modern corporate teams, our report comes in two formats: a printable PDF and a data-rich Excel sheet. This package is optimized for internal analysis. Unlimited users allowed within one corporate location (e.g., regional office).
$4999

The report will be delivered in printable PDF format along with the report’s data Excel sheet. This license offers 100 Free Analyst hours where the client can utilize Credence Research Inc. research team. Permitted for unlimited global use by all users within the purchasing corporation, such as all employees of a single company.
$8999

Let us help you

Credence Staff 3

WILLIAM, North America

+1 304 308 1216

Support Staff at Credence Research

KEITH PHILLIPS, Europe

+44 7809 866 263

Lee - CR Sales Staff

LEE VALLANCE, Asia Pacific

+64 22 017 0275

Kieran Jameson

KIERAN JAMESON, Australia

+61 4192 46279

Report delivery within 24 to 48 hours

What people say?

User Review

Thank you for the data! The numbers are exactly what we asked for and what we need to build our business case.

Materials Scientist
(privacy requested)

User Review

The report was an excellent overview of the Industrial Burners market. This report does a great job of breaking everything down into manageable chunks.

Imre Hof
Management Assistant, Bekaert

Trusted By

cr-clients-logos

Request Sample